Parnax Lab (BOM:506128) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab Debt-to-Equity?

Parnax Lab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Parnax Lab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Parnax Lab's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Parnax Lab's Debt-to-Equity or its related term are showing as below:

BOM:506128' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.82 Med: 1.3 Max: 1.81
Current: 0.88

During the past 13 years, the highest Debt-to-Equity Ratio of Parnax Lab was 1.81. The lowest was 0.82. And the median was 1.30.

BOM:506128's Debt-to-Equity is ranked worse than
82.19% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:506128: 0.88

Parnax Lab Debt-to-Equity Historical Data

The historical data trend for Parnax Lab's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnax Lab Debt-to-Equity Chart

Parnax Lab Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

1.17

1.56

1.81

1.43

0.88

Parnax Lab Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.88	N/A	0.88	N/A

Competitive Comparison of Parnax Lab's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnax Lab's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Parnax Lab's Debt-to-Equity falls into.

Parnax Lab Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Parnax Lab's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(393.846	+	153.345)	/	621.541
	=	0.88

Parnax Lab's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Parnax Lab (BOM:506128) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Parnax Lab Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Parnax Lab's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnax Lab (BOM:506128) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022

Website

https://www.naxparlab.com

Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines